Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple scler… Read more
Zenas BioPharma, Inc. Common Stock (ZBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.209x
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has a cash flow conversion efficiency ratio of -0.209x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.12 Million) by net assets ($196.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zenas BioPharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zenas BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mimasu Semiconductor Industry Co. Ltd
MU:MU2
|
0.045x |
|
Zhejiang Wanliyang Transmission Co Ltd
SHE:002434
|
0.065x |
|
Bellevue Gold Limited
PINK:BELGF
|
0.136x |
|
CapitaLand China Trust
PINK:CLDHF
|
0.015x |
|
Mullen Group Ltd
PINK:MLLGF
|
0.097x |
|
Addnode Group AB (publ)
ST:ANOD-B
|
0.119x |
|
Jiangsu Chengxing Phosph-Chemical Co Ltd
SHG:600078
|
0.150x |
|
BKI Investment Company Ltd
AU:BKI
|
0.025x |
Annual Cash Flow Conversion Efficiency for Zenas BioPharma, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Zenas BioPharma, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $312.46 Million | $-119.67 Million | -0.383x | -383.18% |
| 2023-12-31 | $-225.72 Million | $-30.53 Million | 0.135x | -60.39% |
| 2022-12-31 | $-192.29 Million | $-65.65 Million | 0.341x | -- |